TREAT Asia Quality Assessment Scheme (TAQAS) to standardize the outcome of HIV genotypic resistance testing in a group of Asian laboratories

Journal of Virological Methods

Volumn 159, Issue 2, 2009, Pages 185-193

  Land, Sally ^a   Cunningham, Philip ^b   Zhou, Jialun ^b   Frost, Kevin ^c   Katzenstein, David ^d   Kantor, Rami ^e   Chen, Yi Ming Arthur ^f   Oka, Shinichi ^g   DeLong, Allison ^e   Sayer, David ^h   Smith, Jeffery ^c   Dax, Elizabeth M ^a   Law, Matthew ^b  

^a National Serology Reference Laboratory   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

^c Amer Foundation for AIDS Research   (United States)

^d STANFORD UNIVERSITY   (United States)

^e BROWN UNIVERSITY   (United States)

^f AIDS Prevention and Research Center   (Taiwan)

^g NATIONAL CENTER FOR GLOBAL HEALTH AND MEDICINE   (Japan)

^h Conexio Genomics ^*  (Australia)

Author keywords

Drug resistance; Genotyping; HIV; Quality assessment; TAQAS

Indexed keywords

ANTIVIRAL RESISTANCE; ARTICLE; CONTROLLED STUDY; DATA BASE; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; LABORATORY; METHODOLOGY; NONHUMAN; NUCLEOTIDE SEQUENCE; PLASMA; PRIORITY JOURNAL; QUALITY CONTROL; STANDARDIZATION; SUPERNATANT; TREAT ASIA QUALITY ASSESSMENT SCHEME; VIRUS MUTATION;

ASIA; DRUG RESISTANCE, VIRAL; HIV-1; HUMANS; LABORATORIES; MICROBIAL SENSITIVITY TESTS; QUALITY ASSURANCE, HEALTH CARE;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 67349098439     PISSN: 01660934     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jviromet.2009.03.016     Document Type: Article

References (34)

1. Bennett D.E., Bertagnolio S., Sutherland D., and Gilks C.F. The World Health Organization's global strategy for prevention and assessment of HIV drug resistance. Antiviral Ther. 13 (2008) 1-13
2. de Luca A., Antinori A., di Giambenedetto S., Cingolani A., Perno C.F., and Cauda R. Interpretation systems for genotypic drug resistance of HIV-1. Scand. J. Infect. Dis. Suppl. 106 (2003) 29-34
3. Demeter L.M., D'Aquila R., Weislow O., Lorenzo E., Erice A., Fitzgibbon J., Shafer R., Richman D., Howard T.M., Zhao Y., Fisher E., Huang D., Mayers D., Sylvester S., Arens M., Sannerud K., Rasheed S., Johnson V., Kuritzkes D., Reichelderfer P., Japour A., and ACTG Sequencing Working Group. AIDS Clinical Trials Group. Interlaboratory concordance of DNA sequence analysis to detect reverse transcriptase mutations in HIV-1 proviral DNA. J. Virol. Methods 75 (1998) 93-104
4. Descamps D., Delaugerre C., Masquelier B., Ruffault A., Marcelin A.-G., Izopet J., Chaix M.-L., Calvez V., Brun-Vezinet F., Costagliola D., and The ANTS Resistance Group. Repeated HIV-1 resistance genotyping external quality assessments improve virology laboratory performance. J. Med. Virol. 78 (2006) 159-160
5. Erali M., Page S., Reimer L.G., and Hillyard D.R. Human Immunodeficiency Virus Type 1 drug resistance testing; a comparison of three sequence- based methods. J. Clin. Microbiol. 39 (2001) 2157-2165
6. Fox Z.V., Geretti A.M., Kjaer J., Dragsted U.B., Phillips A.N., Gerstoft J., Staszewski S., Clotet B., von Wyl V., and Lundgren J.D. The ability of four genotypic interpretation systems to predict virological response to ritonavir-boosted protease inhibitors. AIDS 21 (2007) 2033-2042
7. French ANRS (National Agency for AIDS Research) AC11 Resistance Algorithm, 2008. http://www.hivfrenchresistance.org/table.html accessed 25/07/2008.
8. Fujisaki S., Fujisaki S., Ibe S., Asagi T., Itoh T., Yoshida S., Koike T., Oie M., Konda M., Sadamasu K., Nagashima M., Gatanaga H., Matsuda M., Ueda M., Masakane A., Hata M., Mizogami Y., Mori H., Minami R., Okada K., Watanabe K., Shirasaka T., Oka S., Sugiura W., and Kaneda T. Performance and quality assurance of genotypic drug-resistance testing for human immunodeficiency Virus Type 1 in Japan. Jpn. J. Infect. Dis. 60 (2007) 113-117
9. Galli R.A., Sattha B., Wynhoven B., O'Shaughnessy M.V., and Harrigan P.R. Sources and magnitude of intralaboratory variability in a sequence-based genotypic assay for Human Immunodeficiency Virus Type 1 drug resistance. J. Clin. Microbiol. 41 (2003) 2900-2907
10. Geretti A.M. Clinical implications of HIV drug resistance to nucleoside and nucleotide reverse transcriptase inhibitors. AIDS Rev. 8 (2006) 210-220
11. Grover D., Copas A., Green H., Edwards S.G., Dunn D.T., Sabin C., Phillips A., Allen E., and Pillay D. What is the risk of mortality following diagnosis of multidrug-resistant HIV-1?. J. Antimicrobial. Chemother. 61 (2008) 705-713
12. Hirsch M.S., Brun-Vézinet F., D'Aquila R.T., Hammer S.M., Johnson V.A., Kuritzkes D.R., Loveday C., Mellors J.W., Clotet B., Conway B., Demeter L.M., Vella S., Jacobsen D.M., and Richman D.D. Antiretroviral drug resistance testing in adult HIV-1 infection: recommendations of an International AIDS Society-USA panel. JAMA 283 (2000) 2417-2426
13. Hirsch M.S., Brun-Vézinet F., Clotet B., Conway B., Kuritzkes D.R., D'Aquila R.T., Demeter L.M., Hammer S.M., Johnson V.A., Loveday C., Mellors J.W., Jacobsen D.M., and Richman D.D. Antiretroviral drug resistance testing in adults infected with human immunodeficiency virus type 1: 2003 recommendations of an International AIDS Society-USA Panel. Clin. Infect. Dis. 37 (2003) 113-128
14. Huang D.D., Eshleman S.H., Brambilla D.J., Palumbo P.E., and Bremer J.W. Evaluation of the editing process in Human Immunodeficiency Virus Type 1 genotyping. J. Clin. Microbiol. 41 (2003) 3265-3272
15. Johnson V.A., Brun-Vézinet F., Clotet B., Kuritzkes D.R., Pillay D., Schapiro J.M., and Richman D.D. Update of the drug resistance mutations in HIV-1: fall 2006. Top. HIV Med. 14 (2006) 125-130
16. Kijak G.H., Rubio A.E., Pampuro S.E., Zala C., Cahn P., Galli R., Montaner J.S., and Salomón H. Discrepant results in the interpretation of HIV-1 drug-resistance genotypic data among widely used algorithms. HIV Med. 4 (2003) 72-78
17. Korn K., Reil H., Walter H., and Schmidt B. Quality control trial for human immunodeficiency virus type 1 drug resistance testing using clinical samples reveals problems with detecting minority species and interpretation of test results. J. Clin. Microbiol. 41 (2003) 3559-3565
18. Land S., Sayer D., Gizzarelli L., Birch C., Emery S., Hales G., French M., and Dax E.M. An international external quality assessment scheme to standardise the interpretation of HIV-1 genotypic antiretroviral resistance testing. XV International AIDS Conference abstract MoPeB3086. 11-16 July 2004 (2004)
19. Neuwald P.D., Funelas M.B., DelCarmen J.P., Raybold A.W., and Jorgensen P.A. Results of the 2001 AcroMetrix HIV-1 resistance proficiency program. J. Clin. Virol. 25 (2002) S55-S63
20. Porter K., Babiker A., Bhaskaran K., Darbyshire J., Pezzotti P., Porter K., Walker A.S., and CASCADE Collaboration. Determinants of survival following HIV-1 seroconversion after the introduction of HAART. Lancet 18 (2003) 1267-1274
21. Quint W.G.V., Heijtink R.A., Schirm J., Gerlich W.H., and Niesters H.G.M. Reliability of methods for Hepatitis B DNA detection. J. Clin. Microbiol. 33 (1995) 225-228
22. Ravela J., Betts B.J., Brun-Vézinet F., Vandamme A.M., Descamps D., van Laethem K., Smith K., Schapiro J.M., Winslow D.L., Reid C., and Shafer R.W. HIV-1 protease and reverse transcriptase mutation patterns responsible for discordances between genotypic drug resistance interpretation algorithms. J. Acquir. Immune Defic. Syndr. 1 (2003) 8-14
23. Ross L., Boulmé R., Fisher R., Hernandez J., Florance A., Schmit J.C., and Williams V. A direct comparison of drug susceptibility to HIV type 1 from antiretroviral experienced subjects as assessed by the antivirogram and PhenoSense assays and by seven resistance algorithms. AIDS Res. Hum. Retroviruses 21 (2005) 933-939
24. Salkin I.F., Limberger R.J., and Stasik D. Commentary on the objectives and efficacy of proficiency testing in microbiology. J. Clin. Microbiol. 35 (1997) 1921-1923
25. Sayer D.C., Land S., Gizzarelli L., French M., Hales G., Emery S., Christiansen F.T., and Dax E.M. Quality assessment program for genotypic antiretroviral testing improves detection of drug resistance mutations. J. Clin. Microbiol. 41 (2003) 227-236
26. Schirm J., van Loon A.M., Valentine-Thon E., Klapper P., Reid J., and Cleator G.M. External quality assessment programme for qualitative and quantitative detection of Hepatitis C virus RNA in diagnostic virology. J. Clin. Microbiol. 40 (2002) 2973-2980
27. Schuurman R., Demeter L., Reichelderfer P., Tijnagel J., de Groot T., and Boucher C. Worldwide evaluation of DNA sequencing approaches for identification of drug resistance mutations in the Human Immunodeficiency Virus Type 1 reverse transcriptase. J. Clin. Microbiol. 37 (1999) 2291-2296
28. Schuurman R., Brambilla D., de Groot T., Huang D., Land S., Bremer J., Benders I., and Boucher C. Underestimation of HIV Type 1 drug resistance mutations: results from the ENVA-2 genotyping proficiency program. AIDS Res. Hum. Retroviruses 4 (2002) 243-248
29. Shafer R.W., Hertogs K., Zolopa A.R., Warford A., Bollr S., Betts B.J., Merigan T.C., Harrigan R., and Larder B.A. High degree of interlaboratory reproducibility of Human Immunodeficiency Virus Type 1 protease and reverse transcriptase sequencing of plasma samples from heavily treated patients. J. Clin. Microbiol. 39 (2001) 1522-1529
30. Shafer R.W. Genotypic testing for Human Immunodeficiency Type 1 drug resistance. Clin. Micro. Rev. 15 (2002) 247-277
31. Snoeck J., Kantor R., Shafer R.W., van Laethem K., Deforche K., Carvalho A.P., Wynhoven B., Soares M.A., Cane P., Clarke J., Pillay C., Sirivichayakul S., Ariyoshi K., Holguin A., Rudich H., Rodrigues R., Bouzas M.B., Brun-Vézinet F., Reid C., Cahn P., Brigido L.F., Grossman Z., Soriano V., Sugiura W., Phanuphak P., Morris L., Weber J., Pillay D., Tanuri A., Harrigan R.P., Camacho R., Schapiro J.M., Katzenstein D., and Vandamme A.M. Discordances between interpretation algorithms for genotypic resistance to protease and reverse transcriptase inhibitors of human immunodeficiency virus are subtype dependent. Antimicrob. Agents Chemother. 50 (2006) 694-701
32. Stanford University Drug Resistance Database, 2008. http://hivdb.stanford.edu/pages/algs/HIVdb.html accessed on 25/07/2008.
33. Valentine-Thon E., van Loon A.M., Schirm J., Reid J., Klapper P., and Cleator G.M. European proficiency testing programme of molecular detection and Quantitation of Hepatitis B virus DNA. J. Clin. Microbiol. 39 (2001) 4407-4412
34. Vandamme A.M., Sonnerborg A., Ait-Khaled M., Albert J., Asjo B., Bacheler L., Banhegyi D., Boucher C., Brun-Vézinet F., Camacho R., Clevenbergh P., Clumeck N., Dedes N., de Luca A., Doerr H.W., Faudon J.L., Gatti G., Gerstoft J., Hall W.W., Hatzakis A., Hellmann N., Horban A., Lundgren J.D., Kempf D., Miller M., Miller V., Myers T.W., Nielsen C., Opravil M., Palmisano L., Perno C.F., Phillips A., Pillay D., Pumarola T., Ruiz L., Salminen M., Schapiro J., Schmidt B., Schmit J.C., Schuurman R., Shulse E., Soriano V., Staszewski S., Vella S., Youle M., Ziermann R., and Perrin L. Updated European recommendations for the clinical use of HIV drug resistance testing. Antiviral Ther. 9 (2004) 829-848